59 related articles for article (PubMed ID: 9667965)
1. Selective endothelin A receptor antagonists. 4. Discovery and structure-activity relationships of stilbene acid and alcohol derivatives.
Astles PC; Brown TJ; Halley F; Handscombe CM; Harris NV; McCarthy C; McLay IM; Lockey P; Majid T; Porter B; Roach AG; Smith C; Walsh R
J Med Chem; 1998 Jul; 41(15):2745-53. PubMed ID: 9667965
[TBL] [Abstract][Full Text] [Related]
2. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
[TBL] [Abstract][Full Text] [Related]
5. Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteries.
Liang F; Glascock CB; Schafer DL; Sandoval J; Cable L; Melvin L; Hartman JC; Pitts KR
Can J Physiol Pharmacol; 2010 Aug; 88(8):840-9. PubMed ID: 20725142
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
[TBL] [Abstract][Full Text] [Related]
7. 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
Winn M; von Geldern TW; Opgenorth TJ; Jae HS; Tasker AS; Boyd SA; Kester JA; Mantei RA; Bal R; Sorensen BK; Wu-Wong JR; Chiou WJ; Dixon DB; Novosad EI; Hernandez L; Marsh KC
J Med Chem; 1996 Mar; 39(5):1039-48. PubMed ID: 8676339
[TBL] [Abstract][Full Text] [Related]
8. Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.
Astles PC; Brown TJ; Halley F; Handscombe CM; Harris NV; Majid TN; McCarthy C; McLay IM; Morley A; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 2000 Mar; 43(5):900-10. PubMed ID: 10715156
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
Patt WC; Edmunds JJ; Repine JT; Berryman KA; Reisdorph BR; Lee C; Plummer MS; Shahripour A; Haleen SJ; Keiser JA; Flynn MA; Welch KM; Reynolds EE; Rubin R; Tobias B; Hallak H; Doherty AM
J Med Chem; 1997 Mar; 40(7):1063-74. PubMed ID: 9089328
[TBL] [Abstract][Full Text] [Related]
11. Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.
Tasker AS; Sorensen BK; Jae HS; Winn M; von Geldern TW; Dixon DB; Chiou WJ; Dayton BD; Calzadila S; Hernandez L; Marsh KC; WuWong JR; Opgenorth TJ
J Med Chem; 1997 Jan; 40(3):322-30. PubMed ID: 9022798
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists.
Wu C; Chan MF; Stavros F; Raju B; Okun I; Castillo RS
J Med Chem; 1997 May; 40(11):1682-9. PubMed ID: 9171877
[TBL] [Abstract][Full Text] [Related]
13. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptors in lower esophageal sphincter circular smooth muscle.
Huang SC
Regul Pept; 2005 Apr; 127(1-3):27-35. PubMed ID: 15680467
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities.
Alexopoulos K; Fatseas P; Melissari E; Vlahakos D; Roumelioti P; Mavromoustakos T; Mihailescu S; Paredes-Carbajal MC; Mascher D; Matsoukas J
J Med Chem; 2004 Jun; 47(13):3338-52. PubMed ID: 15189031
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
Liu G; Kozmina NS; Winn M; von Geldern TW; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1999 Sep; 42(18):3679-89. PubMed ID: 10479299
[TBL] [Abstract][Full Text] [Related]
17. Azole endothelin antagonists. 2. Structure-activity studies.
von Geldern TW; Kester JA; Bal R; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):968-81. PubMed ID: 8632420
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.
Riechers H; Albrecht HP; Amberg W; Baumann E; Bernard H; Böhm HJ; Klinge D; Kling A; Müller S; Raschack M; Unger L; Walker N; Wernet W
J Med Chem; 1996 May; 39(11):2123-8. PubMed ID: 8667356
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 increases endothelin receptor A levels and action in cultured rat aortic smooth muscle cells.
Kwok CF; Juan CC; Shih KC; Hwu CM; Jap TS; Ho LT
J Cell Biochem; 2005 Apr; 94(6):1126-34. PubMed ID: 15668985
[TBL] [Abstract][Full Text] [Related]
20. Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.
Amberg W; Hergenröder S; Hillen H; Jansen R; Kettschau G; Kling A; Klinge D; Raschack M; Riechers H; Unger L
J Med Chem; 1999 Aug; 42(16):3026-32. PubMed ID: 10447946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
